In recent years the use of immunomodulating therapy to treat various cancers has been on
the rise. Three checkpoint inhibitors have been approved by the Food and Drug …

Background Since 2011 six immune checkpoint inhibitors (ICI) have been approved to treat
patients with many advanced solid tumor and hematological malignancies to improve their …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Objective To better define the rare adverse event (AE) of diabetes mellitus associated with
immune checkpoint inhibitors (ICIs). Design and methods We report the case of a lung …

Immune checkpoint inhibitors (ICIs) belong to a new group of anticancer drugs targeting T-
cell proteins involved in the activation of immune response toward malignancies. Their …

Background Growing evidence has suggested that immune-related genes play crucial roles
in the development and progression of hepatocellular carcinoma (HCC). Nevertheless, the …

Immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 (PD-1) and its ligand
PD-L1 and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibodies, are …

Background: Inhibitory antibodies against cytotoxic T lymphocyte antigen-4 (CTLA-4) and
programmed cell death-1 (PD-1) have antitumor efficacy and are now standard of care in the …

Immune checkpoint inhibitors (ICIs) targeting against programmed cell death-1 (PD-1) and
cytotoxic T-lymphocyte antigen-4 (CTLA-4) have shown efficacy in cancer treatment …

Immune checkpoint inhibitors (ICIs) are a group of drugs employed in the treatment of
various types of malignant tumors and improve the therapeutic effect. ICIs blocks negative co …